Scientists are increasingly examining retatrutide, a novel drug developed by Eli Lilly, as a significant step in physique reduction . Distinct from many earlier approaches, retatrutide is a double -action receptor targeting simultaneously GLP-1 and GIP, hormones that affect hunger and glucose regul